ZAI LAB(ZLAB) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates – Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43% y-o-y growth at constant exchange rate (CER) ® – VYVGART (efgartigimod alfa injection) sales of$ 13.2 million for the first quarter of 2024, driven by increased patient access; an estimated 2,700 new patients were treated with VYVGART in the first quarter of 2024 – Regulatory reviews ongoing for sulbactam-dur ...